Omeros Corporation - Asset Resilience Ratio
Omeros Corporation (OMER) has an Asset Resilience Ratio of 18.14% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Omeros Corporation debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2024)
This chart shows how Omeros Corporation's Asset Resilience Ratio has changed over time. See OMER net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Omeros Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Omeros Corporation (OMER) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $33.69 Million | 18.14% |
| Total Liquid Assets | $33.69 Million | 18.14% |
Asset Resilience Insights
- Good Liquidity Position: Omeros Corporation maintains a healthy 18.14% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Omeros Corporation Industry Peers by Asset Resilience Ratio
Compare Omeros Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Omeros Corporation (2007–2024)
The table below shows the annual Asset Resilience Ratio data for Omeros Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 31.30% | $86.73 Million | $277.08 Million | -12.25pp |
| 2023-12-31 | 43.55% | $164.74 Million | $378.27 Million | +12.43pp |
| 2022-12-31 | 31.12% | $183.91 Million | $590.97 Million | +17.65pp |
| 2021-12-31 | 13.47% | $56.46 Million | $419.27 Million | -55.28pp |
| 2020-12-31 | 68.74% | $124.45 Million | $181.04 Million | +26.61pp |
| 2019-12-31 | 42.13% | $57.70 Million | $136.97 Million | -14.82pp |
| 2018-12-31 | 56.95% | $54.64 Million | $95.94 Million | -12.12pp |
| 2017-12-31 | 69.08% | $80.36 Million | $116.33 Million | +5.00pp |
| 2016-12-31 | 64.07% | $43.11 Million | $67.28 Million | +9.17pp |
| 2015-12-31 | 54.90% | $26.90 Million | $48.99 Million | -4.00pp |
| 2014-12-31 | 58.90% | $6.53 Million | $11.09 Million | -18.01pp |
| 2013-12-31 | 76.91% | $12.72 Million | $16.54 Million | -1.47pp |
| 2012-12-31 | 78.38% | $20.83 Million | $26.57 Million | +2.16pp |
| 2011-12-31 | 76.22% | $20.57 Million | $26.98 Million | -8.49pp |
| 2010-12-31 | 84.71% | $38.72 Million | $45.70 Million | -11.14pp |
| 2009-12-31 | 95.85% | $59.48 Million | $62.06 Million | +62.38pp |
| 2008-12-31 | 33.47% | $7.26 Million | $21.68 Million | -33.38pp |
| 2007-12-31 | 66.85% | $18.16 Million | $27.16 Million | -- |
About Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinic… Read more